Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Exosome-SIRPα
- Development stage
- Preclinical
- Lead developer
- ShiftBio
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral, Intravenous
01
Overview
Exosome-SIRPα (also known as SBI-101) is an engineered exosome-based cancer immunotherapy developed by ShiftBio. It is designed to display signal-regulatory protein alpha (SIRPα) on the exosomal membrane using ShiftBio's proprietary Maxisome platform. By presenting SIRPα, the exosomes target and bind to CD47 (the 'don't eat me' signal) overexpressed on tumor cells. This interaction blocks the CD47-SIRPα signaling pathway, preventing immune evasion and significantly enhancing the phagocytosis of cancer cells by macrophages and dendritic cells. SBI-101 is being developed for the treatment of solid tumors, particularly those resistant to PD-1 blockade.
- Other names
- Exosome SIRPαSIRPα-exosomes
02
Targets
CD47 (Cluster of Differentiation 47)SIRPA (Signal-regulatory protein alpha)
Beyond the preview
Go deeper on Exosome-SIRPα.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exosome-SIRPα.